Determined to Make a Difference

Prometheus Biosciences is a forward-thinking biopharmaceutical company that is dedicated to disrupting the treatment paradigm of GI diseases. We will do this by discovering and developing a broad portfolio of novel precision therapeutics and diagnostics that will meaningfully impact patient care.

Our Vision

We harness the power of patient ImmunoMX to eradicate GI Disease.

Our Mission

Bringing breakthrough diagnostic and therapeutic solutions to optimize outcomes for patients throughout their individual healthcare journey

Building the First GI Medicines Platform

1992

1st sample collected. The beginning of our GI Medicines Platform

1995

Prometheus Labs is formed

1996

Prometheus Labs launches 1st diagnostic, pANCA

2012

Prometheus launches Anser®

2017

Precision IBD is formed

2017

Prometheus launches Monitrâ„¢

2019

Precision IBD nominates first clinical candidate mAb, PR200

2019

Precision IBD acquires Prometheus Labs to form Prometheus Biosciences

2020

PR200 enters clinic, first subject dosed

2025

PR200 targeted commercial launch date

Portfolio Milestones